Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 66,324 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 66,324 shares of the firm’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $0.94, for a total value of $62,344.56. Following the completion of the transaction, the insider owned 5,362,588 shares in the company, valued at $5,040,832.72. The trade was a 1.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total value of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.

Werewolf Therapeutics Trading Down 7.6%

Shares of HOWL stock traded down $0.07 on Thursday, hitting $0.85. 465,207 shares of the stock traded hands, compared to its average volume of 732,451. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The firm’s 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.33. The stock has a market capitalization of $41.49 million, a PE ratio of -0.53 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its holdings in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after buying an additional 23,852 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the first quarter worth $71,000. MPM Asset Management LLC raised its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares in the last quarter. MPM Bioimpact LLC raised its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter valued at $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

HOWL has been the topic of several research analyst reports. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities reduced their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Finally, Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.